Teva Pharmaceutical Industries and the Incoming Trump Administration

JERUSALEM (Reuters) – Teva Pharmaceutical Industries (NYSE:TEVA) is optimistic about collaborating with the incoming Trump administration, as stated by CEO Richard Francis on Wednesday.

> "Our job, as always, is to work productively with any administration, and we've shown we can do that, and we will absolutely do that," Francis remarked to Reuters after the company reported strong third-quarter results.

Francis noted that the specifics of Trump’s healthcare and pharmaceutical policies would not be clear until he officially takes office. He also indicated that he anticipates 2025 will continue to show consistent growth for Teva, particularly in branded drugs, an expansion in its generics business, and increased sales of biosimilars.